PGTAZ-7.5 Tablet

What is PGTAZ‑7.5 Tablet?

PGTAZ‑7.5 Tablet is an oral antidiabetic formulation containing Pioglitazone 7.5 mg per tablet. Pioglitazone acts on PPAR‑γ receptors to enhance insulin sensitivity in muscle, fat and liver, thereby improving glucose utilisation and reducing hepatic glucose output.​

Key Benefits

• Helps reduce fasting and post‑prandial blood glucose and improve HbA1c in adults with type 2 diabetes, particularly in insulin‑resistant patients.​

• Low‑dose 7.5 mg pioglitazone has been reported to improve metabolic parameters with a lower incidence of weight gain and fluid retention compared with higher doses.​

Uses & Indications

PGTAZ‑7.5 Tablet is used for:

• Type 2 diabetes mellitus in adults, usually as add‑on therapy when diet, exercise and other oral agents do not provide adequate glycaemic control.​

• Patients in whom a TZD is considered appropriate to improve insulin sensitivity, often combined with metformin, sulfonylureas or DPP‑4 inhibitors.​

It is not indicated for type 1 diabetes or for the treatment of diabetic ketoacidosis.​

Dosage & Directions

The exact schedule is decided by the treating physician.​

• Usual adult regimen for this strength: Pioglitazone 7.5 mg once daily, with or without food, preferably at the same time each day.​

• Tablets should be swallowed whole with water; therapy is typically long term and combined with diet and exercise.​

Dose adjustments or avoidance may be required in hepatic impairment, heart failure or when used with other glucose‑lowering medicines.​

Price & Packaging

On the Ingram Biosciences product page, PGTAZ‑7.5 Tablet is listed at an MRP of ₹95.00, with promotional pricing often around ₹80–₹81 per strip of 10 tablets. Trade listings show bulk or B2B pricing close to ₹60 per 10‑tablet Alu‑Alu strip for distributors.​

The product is supplied in blister strips (generally 10 tablets) packed in printed cartons with strength, composition, batch number, manufacturing and expiry details.​

Side Effects & Safety

Common adverse effects associated with pioglitazone (including 7.5 mg formulations) include:

• Weight gain, peripheral edema (swelling of feet/ankles), mild anaemia and headache.​

• Respiratory tract infections, sinusitis or mild musculoskeletal pain.​

Important but less common risks are fluid retention and worsening heart failure, increased fracture risk (especially in women), and possible bladder‑related concerns seen with higher cumulative exposure. Any new or worsening breathlessness, rapid weight gain, ankle swelling, bone pain, or blood in urine needs prompt medical review.​

Precautions & Contraindications

• Contraindicated in patients with NYHA class III–IV heart failure or a history of heart failure related to TZDs.​

• Avoid or use with extreme caution in active liver disease; liver enzymes should be checked before and periodically during therapy.​

• Caution in patients with fracture risk, macular edema, oedema, or history of bladder cancer; risk–benefit must be carefully assessed.​

Use in pregnancy and breastfeeding should be based on specialist advice; alternative agents are usually preferred.​

10 Frequently Asked Questions (FAQ)

1. What is PGTAZ‑7.5 Tablet used for?
It is used to help control blood sugar in adults with type 2 diabetes, particularly when insulin resistance is prominent and other oral agents are insufficient alone.​

2. How does pioglitazone 7.5 mg work?
It improves the body’s response to insulin by activating PPAR‑γ receptors in fat, muscle and liver, enhancing glucose uptake and reducing hepatic glucose production.​

3. Why a low dose like 7.5 mg?
Clinical data suggest low‑dose pioglitazone (7.5 mg/day) can provide metabolic benefits with fewer adverse effects such as edema and weight gain compared with higher doses.​

4. When should I take PGTAZ‑7.5?
Usually once daily at the same time, with or without food, as advised by your doctor.​

5. Can PGTAZ‑7.5 be combined with metformin or other tablets?
Yes, it is often used with metformin, sulfonylureas or DPP‑4 inhibitors, but this must be individualized and monitored by the physician.​

6. Does pioglitazone cause low blood sugar?
On its own, it rarely causes hypoglycaemia; the risk increases when combined with insulin or secretagogues like sulfonylureas.​

7. What are warning signs related to heart failure?
Shortness of breath, rapid weight gain, swollen legs or ankles, and unusual tiredness may indicate fluid overload and require immediate medical attention.​

8. Is it safe for the liver and kidneys?
Pioglitazone is not recommended in active liver disease; liver tests should be monitored, while usual doses can be used in mild‑to‑moderate renal impairment.​

9. Can it increase fracture risk?
Long‑term use has been associated with a higher fracture risk, especially in women, so bone health monitoring may be advisable.​

10. How long should I continue PGTAZ‑7.5?
Type 2 diabetes is chronic; treatment is generally long term and should not be stopped without your doctor’s advice.​

Quick Tips

• Take PGTAZ‑7.5 Tablet at the same time every day and do not change the dose without medical advice.​

• Watch for ankle swelling, breathlessness or rapid weight gain and report these early to reduce heart‑failure risk.​

• Continue a controlled diet, regular exercise and scheduled blood tests (HbA1c, liver function, lipids) as part of comprehensive diabetes care.​

Why Choose Ingram BioSciences?

PGTAZ‑7.5 Tablet is part of Ingram Biosciences’ Cardio‑Diabetes Care line, alongside DAPING 10, FORMIGRAM‑GZ and LYPGEN 100, offering a full range of oral antidiabetics for Indian clinicians. Ingram operates from Jasola, New Delhi, with trader–manufacturer partnerships, WHO‑GMP‑aligned facilities and a strong PCD/export network, ensuring reliable supply and clear prescriber‑only positioning.​

This makes PGTAZ‑7.5 a credible low‑dose pioglitazone option in the company’s integrated diabetes portfolio.​

Customer Support & Ordering

For medical, distribution or franchise queries about PGTAZ‑7.5 Tablet:

• Company: Ingram Biosciences Pvt Ltd.​

• Delhi Office: Office‑308, 3rd Floor, Living Style Mall, Jasola, New Delhi – 110025, India.​

• Phone / WhatsApp: +91 99997 81444; Mobile: +91 76690 11534.​

• Email: info@ingrambiosciences.in​

PGTAZ‑7.5 Tablet is available via hospitals, retail chemists, PCD/franchise partners and leading e‑pharmacy platforms, and must only be used on the prescription of a registered medical practitioner.